Copyright © 2009 F. A. Moreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. Booth, Cannabis: A History, Banton Books, London, UK, 2003.
2. D. T. Courtwright, Forces of Habit: Drugs and the Making of the Modern World, Harvard University Press, Cambridge, Mass, USA, 2001.
3. A. W. Zuardi, “History of cannabis as a medicine: a review,” Revista Brasileira de Psiquiatria, vol. 28, no. 2, pp. 153–157, 2006. View at Publisher · View at Google Scholar
4. R. Mechoulam, “Marijuana chemistry,” Science, vol. 168, no. 936, pp. 1159–1166, 1970. View at Publisher · View at Google Scholar
5. W. D. M. Paton, “Pharmacology of marijuana,” Annual Review of Pharmacology, vol. 15, pp. 191–220, 1975. View at Publisher · View at Google Scholar · View at PubMed
6. W. A. Devane, F. A. Dysarz, III, M. R. Johnson, L. S. Melvin, and A. C. Howlett, “Determination and characterization of a cannabinoid receptor in rat brain,” Molecular Pharmacology, vol. 34, no. 5, pp. 605–613, 1988.
7. L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner, “Structure of a cannabinoid receptor and functional expression of the cloned cDNA,” Nature, vol. 346, no. 6284, pp. 561–564, 1990. View at Publisher · View at Google Scholar · View at PubMed
8. W. A. Devane, L. Hanus, A. Breuer, et al., “Isolation and structure of a brain constituent that binds to the cannabinoid receptor,” Science, vol. 258, no. 5090, pp. 1946–1949, 1992. View at Publisher · View at Google Scholar
9. R. Mechoulam, S. Ben-Shabat, L. Hanus, et al., “Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors,” Biochemical Pharmacology, vol. 50, no. 1, pp. 83–90, 1995. View at Publisher · View at Google Scholar
10. S. Munro, K. L. Thomas, and M. Abu-Shaar, “Molecular characterization of a peripheral receptor for cannabinoids,” Nature, vol. 365, no. 6441, pp. 61–65, 1993. View at Publisher · View at Google Scholar · View at PubMed
11. M. Rinaldi-Carmona, F. Barth, M. Héaulme, et al., “SR141716A, a potent and selective antagonist of the brain cannabinoid receptor,” FEBS Letters, vol. 350, no. 2-3, pp. 240–244, 1994. View at Publisher · View at Google Scholar
12. S. J. Gatley, A. N. Gifford, N. D. Volkow, R. Lan, and A. Makriyannis, “${}^{123}\text{I}$-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid ${\text{CB}}_1$ receptors,” European Journal of Pharmacology, vol. 307, no. 3, pp. 331–338, 1996. View at Publisher · View at Google Scholar
13. M. Herkenham, A. B. Lynn, M. R. Johnson, L. S. Melvin, B. R. de Costa, and K. C. Rice, “Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study,” The Journal of Neuroscience, vol. 11, no. 2, pp. 563–583, 1991.
14. K. Tsou, S. Brown, M. C. Sañudo-Peña, K. Mackie, and J. M. Walker, “Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system,” Neuroscience, vol. 83, no. 2, pp. 393–411, 1998. View at Publisher · View at Google Scholar
15. M. Egertov, D. K. Giang, B. F. Cravatt, and M. R. Elphick, “A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain,” Proceedings of the Royal Society B, vol. 265, no. 1410, pp. 2081–2085, 1998. View at Publisher · View at Google Scholar · View at PubMed
16. R. I. Wilson and R. A. Nicoll, “Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses,” Nature, vol. 410, no. 6828, pp. 588–592, 2001. View at Publisher · View at Google Scholar · View at PubMed
17. A. C. Howlett, F. Barth, T. I. Bonner, et al., “International Union of Pharmacology. XXVII. Classification of cannabinoid receptors,” Pharmacological Reviews, vol. 54, no. 2, pp. 161–202, 2002. View at Publisher · View at Google Scholar
18. A. Giuffrida, M. Beltramo, and D. Piomelli, “Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 1, pp. 7–14, 2001.
19. M. K. McKinney and B. E. Cravatt, “Structure and function of fatty acid amide hydrolase,” Annual Review of Biochemistry, vol. 74, pp. 411–432, 2005. View at Publisher · View at Google Scholar · View at PubMed
20. P. Pacher, S. Bátkai, and G. Kunos, “The endocannabinoid system as an emerging target of pharmacotherapy,” Pharmacological Reviews, vol. 58, no. 3, pp. 389–462, 2006. View at Publisher · View at Google Scholar · View at PubMed
21. A. J. Brown, “Novel cannabinoid receptors,” British Journal of Pharmacology, vol. 152, no. 5, pp. 567–575, 2007. View at Publisher · View at Google Scholar · View at PubMed
22. M. R. Price, G. L. Baillie, A. Thomas, et al., “Allosteric modulation of the cannabinoid ${\text{CB}}_1$ receptor,” Molecular Pharmacology, vol. 68, no. 5, pp. 1484–1495, 2005. View at Publisher · View at Google Scholar · View at PubMed
23. M. D. Van Sickle, M. Duncan, P. J. Kingsley, et al., “Identification and functional characterization of brainstem cannabinoid ${\text{CB}}_2$ receptors,” Science, vol. 310, no. 5746, pp. 329–332, 2005. View at Publisher · View at Google Scholar · View at PubMed
24. J.-P. Gong, E. S. Onaivi, H. Ishiguro, et al., “Cannabinoid CB2 receptors: immunohistochemical localization in rat brain,” Brain Research, vol. 1071, no. 1, pp. 10–23, 2006. View at Publisher · View at Google Scholar · View at PubMed
25. M. P. Viveros, E. M. Marco, and S. E. File, “Endocannabinoid system and stress and anxiety responses,” Pharmacology Biochemistry and Behavior, vol. 81, no. 2, pp. 331–342, 2005. View at Publisher · View at Google Scholar · View at PubMed
26. F. G. Graeff, “Neuroanatomy and neurotransmitter regulation of defensive behaviours and related emotions in mammals,” Brazilian Journal of Medical and Biological Research, vol. 27, no. 4, pp. 811–829, 1994.
27. N. McNaughton and J. A. Gray, “Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety,” Journal of Affective Disorders, vol. 61, no. 3, pp. 161–176, 2000. View at Publisher · View at Google Scholar
28. N. McNaughton and P. J. Corr, “A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance,” Neuroscience & Biobehavioral Reviews, vol. 28, no. 3, pp. 285–305, 2004. View at Publisher · View at Google Scholar · View at PubMed
29. R. Bandler, K. A. Keay, N. Floyd, and J. Price, “Central circuits mediating patterned autonomic activity during active vs. passive emotional coping,” Brain Research Bulletin, vol. 53, no. 1, pp. 95–104, 2000. View at Publisher · View at Google Scholar
30. R. Bandler and A. Depaulis, “Elicitation of intraspecific defence reactions in the rat from midbrain periaqueductal grey by microinjection of kainic acid, without neurotoxic effects,” Neuroscience Letters, vol. 88, no. 3, pp. 291–296, 1988. View at Publisher · View at Google Scholar
31. N. A. Patel, R. L. Moldow, J. A. Patel, G.-D. Wu, and S. L. Chang, “Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain,” Brain Research, vol. 797, no. 2, pp. 225–233, 1998. View at Publisher · View at Google Scholar
32. C.-L. Chin, A. E. Tovcimak, V. P. Hradil, et al., “Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI,” British Journal of Pharmacology, vol. 153, no. 2, pp. 367–379, 2008. View at Publisher · View at Google Scholar · View at PubMed
33. W. J. Martin, S. L. Patrick, P. O. Coffin, K. Tsou, and J. M. Walker, “An examination of the central sites of action of cannabinoid-induced antinociception in the rat,” Life Sciences, vol. 56, no. 23-24, pp. 2103–2109, 1995. View at Publisher · View at Google Scholar
34. J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sañudo-Peña, “Pain modulation by release of the endogenous cannabinoid anandamide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 21, pp. 12198–12203, 1999. View at Publisher · View at Google Scholar
35. A. G. Hohmann and R. L. Suplita, II, “Endocannabinoid mechanisms of pain modulation,” The AAPS Journal, vol. 8, no. 4, pp. E693–E708, 2006. View at Publisher · View at Google Scholar · View at PubMed
36. D. P. Finn, M. D. Jhaveri, S. R. G. Beckett, et al., “Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats,” Neuropharmacology, vol. 45, no. 5, pp. 594–604, 2003. View at Publisher · View at Google Scholar
37. E. S. Onaivi, M. R. Green, and B. R. Martin, “Pharmacological characterization of cannabinoids in the elevated plus maze,” Journal of Pharmacology and Experimental Therapeutics, vol. 253, no. 3, pp. 1002–1009, 1990.
38. E. Valjent, J. M. Mitchell, M.-J. Besson, J. Caboche, and R. Maldonado, “Behavioural and biochemical evidence for interactions between ${\mathrm{\Delta }}^9$-tetrahydrocannabinol and nicotine,” British Journal of Pharmacology, vol. 135, no. 2, pp. 564–578, 2002. View at Publisher · View at Google Scholar · View at PubMed
39. F. Berrendero and R. Maldonado, “Involvement of the opioid system in the anxiolytic-like effects induced by ${\mathrm{\Delta }}^9$-tetrahydrocannabinol,” Psychopharmacology, vol. 163, no. 1, pp. 111–117, 2002. View at Publisher · View at Google Scholar · View at PubMed
40. S. Patel and C. J. Hillard, “Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signalling,” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 1, pp. 304–311, 2006. View at Publisher · View at Google Scholar · View at PubMed
41. D. Braida, V. Limonta, L. Malabarba, A. Zani, and M. Sala, “5-H${\text{T}}_{1\text{A}}$ receptors are involved in the anxiolytic effect of ${\mathrm{\Delta }}^9$-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats,” European Journal of Pharmacology, vol. 555, no. 2-3, pp. 156–163, 2007. View at Publisher · View at Google Scholar · View at PubMed
42. N. L. Schramm-Sapyta, Y. M. Cha, S. Chaudhry, W. A. Wilson, H. S. Swartzwelder, and C. M. Kuhn, “Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats,” Psychopharmacology, vol. 191, no. 4, pp. 867–877, 2007. View at Publisher · View at Google Scholar · View at PubMed
43. T. Rubino, M. Sala, D. Viganò, et al., “Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral ${\mathrm{\Delta }}^9$-tetrahydrocannabinol in rats,” Neuropsychopharmacology, vol. 32, no. 9, pp. 2036–2045, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. F. S. Guimarães, T. M. Chiaretti, F. G. Graeff, and A. W. Zuardi, “Antianxiety effect of cannabidiol in the elevated plus-maze,” Psychopharmacology, vol. 100, no. 4, pp. 558–559, 1990. View at Publisher · View at Google Scholar
45. F. S. Guimarães, J. C. de Aguiar, R. Mechoulam, and A. Breuer, “Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze,” General Pharmacology, vol. 25, no. 1, pp. 161–164, 1994. View at Publisher · View at Google Scholar
46. F. A. Moreira, D. C. Aguiar, and F. S. Guimarães, “Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 8, pp. 1466–1471, 2006. View at Publisher · View at Google Scholar · View at PubMed
47. L. B. Resstel, S. R. L. Joca, F. A. Moreira, F. M. A. Corrêaa, and F. S. Guimarães, “Effects of cannabidiol and diazepam on behavioural and cardiovascular responses induced by contextual conditioned fear in rats,” Behavioural Brain Research, vol. 172, no. 2, pp. 294–298, 2006. View at Publisher · View at Google Scholar · View at PubMed
48. D. Giuliani, F. Ferrari, and A. Ottani, “The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress,” Pharmacological Research, vol. 41, no. 1, pp. 45–51, 2000. View at Publisher · View at Google Scholar
49. W. Jiang, Y. Zhang, L. Xiao, et al., “Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects,” The Journal of Clinical Investigation, vol. 115, no. 11, pp. 3104–3116, 2005. View at Publisher · View at Google Scholar · View at PubMed
50. M. N. Hill and B. B. Gorzalka, “Enhancement of anxiety-like responsiveness to the cannabinoid ${\text{CB}}_1$ receptor agonist HU-210 following chronic stress,” European Journal of Pharmacology, vol. 499, no. 3, pp. 291–295, 2004. View at Publisher · View at Google Scholar · View at PubMed
51. J. Haller, B. Varga, C. Ledent, and T. F. Freund, “CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents,” Behavioural Pharmacology, vol. 15, no. 4, pp. 299–304, 2004. View at Publisher · View at Google Scholar
52. J. Haller, F. Mátyás, K. Soproni, et al., “Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission,” European Journal of Neuroscience, vol. 25, no. 8, pp. 2445–2456, 2007. View at Publisher · View at Google Scholar · View at PubMed
53. C. Arévalo, R. de Miguel, and R. Hernández-Tristán, “Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters,” Pharmacology Biochemistry and Behavior, vol. 70, no. 1, pp. 123–131, 2001. View at Publisher · View at Google Scholar
54. S. Marín, E. Marco, M. Biscaia, et al., “Involvement of the $\kappa$-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats,” Pharmacology Biochemistry and Behavior, vol. 74, no. 3, pp. 649–656, 2003. View at Publisher · View at Google Scholar
55. E. M. Marco, L. Pérez-Alvarez, E. Borcel, et al., “Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats,” Behavioural Pharmacology, vol. 15, no. 1, pp. 21–27, 2004. View at Publisher · View at Google Scholar
56. R. F. Genn, S. Tucci, E. Marco, M.-P. Viveros, and S. E. File, “Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55,940 in animal tests of anxiety,” Journal of Psychopharmacology, vol. 17, p. A27, 2003.
57. R. F. Genn, S. Tucci, E. M. Marco, M. P. Viveros, and S. E. File, “Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test,” Pharmacology Biochemistry and Behavior, vol. 77, no. 3, pp. 567–573, 2004. View at Publisher · View at Google Scholar · View at PubMed
58. A. Chakrabarti, J. E. Ekuta, and E. S. Onaivi, “Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice,” Brain Research Bulletin, vol. 45, no. 1, pp. 67–74, 1998. View at Publisher · View at Google Scholar
59. M. Scherma, J. Medalie, W. Fratta, et al., “The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition,” Neuropharmacology, vol. 54, no. 1, pp. 129–140, 2008. View at Publisher · View at Google Scholar · View at PubMed
60. M. Bortolato, P. Campolongo, R. A. Mangieri, et al., “Anxiolytic-like properties of the anandamide transport inhibitor AM404,” Neuropsychopharmacology, vol. 31, no. 12, pp. 2652–2659, 2006. View at Publisher · View at Google Scholar · View at PubMed
61. S. Kathuria, S. Gaetani, D. Fegley, et al., “Modulation of anxiety through blockade of anandamide hydrolysis,” Nature Medicine, vol. 9, no. 1, pp. 76–81, 2003. View at Publisher · View at Google Scholar · View at PubMed
62. P. S. Naidu, S. A. Varvel, K. Ahn, B. F. Cravatt, B. R. Martin, and A. H. Lichtman, “Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality,” Psychopharmacology, vol. 192, no. 1, pp. 61–70, 2007. View at Publisher · View at Google Scholar · View at PubMed
63. F. A. Moreira, N. Kaiser, K. Monory, and B. Lutz, “Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors,” Neuropharmacology, vol. 54, no. 1, pp. 141–150, 2008. View at Publisher · View at Google Scholar · View at PubMed
64. M. Rutkowska, J. Jamontt, and H. Gliniak, “Effects of cannabinoids on the anxiety-like response in mice,” Pharmacological Reports, vol. 58, no. 2, pp. 200–206, 2006.
65. M. Navarro, E. Hernández, R. M. Muñoz, et al., “Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat,” NeuroReport, vol. 8, no. 2, pp. 491–496, 1997. View at Publisher · View at Google Scholar
66. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T. F. Freund, “The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety,” European Journal of Neuroscience, vol. 16, no. 7, pp. 1395–1398, 2002. View at Publisher · View at Google Scholar
67. G. Griebel, J. Stemmelin, and B. Scatton, “Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents,” Biological Psychiatry, vol. 57, no. 3, pp. 261–267, 2005. View at Publisher · View at Google Scholar · View at PubMed
68. R. J. Rodgers, P. M. Evans, and A. Murphy, “Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice,” Behavioural Pharmacology, vol. 16, no. 5-6, pp. 405–413, 2005. View at Publisher · View at Google Scholar
69. J. W. Kasckow, J. J. Mulchahey, and T. D. Geracioti, Jr., “Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviours,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 28, no. 2, pp. 291–295, 2004. View at Publisher · View at Google Scholar · View at PubMed
70. D. P. Finn, M. D. Jhaveri, S. R. G. Beckett, D. A. Kendall, C. A. Marsden, and V. Chapman, “Cannabinoids modulate ultrasound-induced aversive responses in rats,” Psychopharmacology, vol. 172, no. 1, pp. 41–51, 2004. View at Publisher · View at Google Scholar · View at PubMed
71. F. A. Moreira, D. C. Aguiar, and F. S. Guimarães, “Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray,” Neuropharmacology, vol. 52, no. 3, pp. 958–965, 2007. View at Publisher · View at Google Scholar · View at PubMed
72. S. Pellow and S. E. File, “Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat,” Pharmacology Biochemistry and Behavior, vol. 24, no. 3, pp. 525–529, 1986. View at Publisher · View at Google Scholar
73. S. F. Lisboa, L. B. Resstel, D. C. Aguiar, and F. S. Guimarães, “Activation of cannabinoid ${\text{CB}}_1$ receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test,” European Journal of Pharmacology, vol. 593, no. 1–3, pp. 73–78, 2008. View at Publisher · View at Google Scholar · View at PubMed
74. J. R. Vogel, B. Beer, and D. E. Clody, “A simple and reliable conflict procedure for testing anti-anxiety agents,” Psychopharmacologia, vol. 21, no. 1, pp. 1–7, 1971. View at Publisher · View at Google Scholar
75. M. J. Millan, “The neurobiology and control of anxious states,” Progress in Neurobiology, vol. 70, no. 2, pp. 83–244, 2003. View at Publisher · View at Google Scholar
76. M.-P. Viveros, E.-M. Marco, R. Llorente, and M. López-Gallardo, “Endocannabinoid system and synaptic plasticity: implications for emotional responses,” Neural Plasticity, vol. 2007, Article ID 52908, 12 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
77. A. G. Hohmann, R. L. Suplita, N. M. Bolton, et al., “An endocannabinoid mechanism for stress-induced analgesia,” Nature, vol. 435, no. 7045, pp. 1108–1112, 2005. View at Publisher · View at Google Scholar · View at PubMed
78. L. B. Resstel, S. F. Lisboa, D. C. Aguiar, F. M. A. Corrêa, and F. S. Guimarães, “Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats,” Psychopharmacology, vol. 198, no. 3, pp. 405–411, 2008. View at Publisher · View at Google Scholar · View at PubMed
79. M. S. Fanselow, “Conditional and unconditional components of post-shock freezing,” The Pavlovian Journal of Biological Science, vol. 15, no. 4, pp. 177–182, 1980.
80. L. B. Resstel, S. R. Joca, F. G. Guimarães, and F. M. A. Corrêa, “Involvement of medial prefrontal cortex neurons in behavioural and cardiovascular responses to contextual fear conditioning,” Neuroscience, vol. 143, no. 2, pp. 377–385, 2006. View at Publisher · View at Google Scholar · View at PubMed
81. P. Carrive, J. Lee, and A. Su, “Lidocaine blockade of amygdala output in fear-conditioned rats reduces Fos expression in the ventrolateral periaqueductal gray,” Neuroscience, vol. 95, no. 4, pp. 1071–1080, 1999. View at Publisher · View at Google Scholar
82. P. Carrive, P. Leung, J. Harris, and G. Paxinos, “Conditioned fear to context is associated with increased Fos expression in the caudal ventrolateral region of the midbrain periaqueductal gray,” Neuroscience, vol. 78, no. 1, pp. 165–177, 1997. View at Publisher · View at Google Scholar
83. P. Amorapanth, K. Nader, and J. E. LeDoux, “Lesions of periaqueductal gray dissociate-conditioned freezing from conditioned suppression behaviour in rats,” Learning & Memory, vol. 6, no. 5, pp. 491–499, 1999. View at Publisher · View at Google Scholar
84. J. E. LeDoux, J. Iwata, P. Cicchetti, and D. J. Reis, “Different projections of the central amygdaloid nucleus mediate autonomic and behavioural correlates of conditioned fear,” The Journal of Neuroscience, vol. 8, no. 7, pp. 2517–2529, 1988.
85. C. W. Vaughan, M. Connor, E. E. Bagley, and M. J. Christie, “Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro,” Molecular Pharmacology, vol. 57, no. 2, pp. 288–295, 2000.
86. A. C. Campos and F. S. Guimarães, “Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats,” Psychopharmacology, vol. 199, no. 2, pp. 223–230, 2008. View at Publisher · View at Google Scholar · View at PubMed
87. A.L. Terzian, D.C. Aguiar, F.S. Guimarães, and F.A. Moreira, “Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 Channel (TRPV1) located in the dorsolateral periaqueductal gray,” European Neuropsychopharmacology. In press.
88. N. S. Canteras, “The medial hypothalamic defensive system: hodological organization and functional implications,” Pharmacology Biochemistry and Behavior, vol. 71, no. 3, pp. 481–491, 2002. View at Publisher · View at Google Scholar
89. F. A. Moreira and B. Lutz, “The endocannabinoid system: emotion, learning and addiction,” Addiction Biology, vol. 13, no. 2, pp. 196–212, 2008. View at Publisher · View at Google Scholar · View at PubMed
90. A. W. Zuardi, I. Shirakawa, E. Finkelfarb, and I. G. Karniol, “Action of cannabidiol on the anxiety and other effects produced by ${\mathrm{\Delta }}^9$-THC in normal subjects,” Psychopharmacology, vol. 76, no. 3, pp. 245–250, 1982. View at Publisher · View at Google Scholar
91. A. W. Zuardi, J. A. S. Crippa, J. E. C. Hallak, F. A. Moreira, and F. S. Guimarães, “Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 4, pp. 421–429, 2006. View at Publisher · View at Google Scholar
92. A. W. Zuardi, R. A. Cosme, F. G. Graeff, and F. S. Guimarães, “Effects of ipsapirone and cannabidiol on human experimental anxiety,” Journal of Psychopharmacology, vol. 7, no. 1, pp. 82–88, 1993.
93. J. A. de Souza Crippa, A. W. Zuardi, G. E. J. Garrido, et al., “Effects of cannabidiol (CBD) on regional cerebral blood flow,” Neuropsychopharmacology, vol. 29, no. 2, pp. 417–426, 2004. View at Publisher · View at Google Scholar · View at PubMed
94. T. Bisogno, L. Hanuš, L. De Petrocellis, et al., “Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide,” British Journal of Pharmacology, vol. 134, no. 4, pp. 845–852, 2001. View at Publisher · View at Google Scholar · View at PubMed
95. E. B. Russo, A. Burnett, B. Hall, and K. K. Parker, “Agonistic properties of cannabidiol at 5-HT1a receptors,” Neurochemical Research, vol. 30, no. 8, pp. 1037–1043, 2005. View at Publisher · View at Google Scholar · View at PubMed
96. L. Cristino, L. de Petrocellis, G. Pryce, D. Baker, V. Guglielmotti, and V. Di Marzo, “Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain,” Neuroscience, vol. 139, no. 4, pp. 1405–1415, 2006.
97. R. L. Nogueira and F. G. Graeff, “Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion,” Pharmacology Biochemistry and Behavior, vol. 52, no. 1, pp. 1–6, 1995. View at Publisher · View at Google Scholar
98. J. R. Raymond, Y. V. Mukhin, T. W. Gettys, and M. N. Garnovskaya, “The recombinant 5-H${\text{T}}_{1\text{A}}$ receptor: G protein coupling and signalling pathways,” British Journal of Pharmacology, vol. 127, no. 8, pp. 1751–1764, 1999. View at Publisher · View at Google Scholar · View at PubMed
99. G. A. Carrasco and L. D. Van de Kar, “Neuroendocrine pharmacology of stress,” European Journal of Pharmacology, vol. 463, no. 1–3, pp. 235–272, 2003. View at Publisher · View at Google Scholar
100. J. M. Zanoveli, R. L. Nogueira, and H. Zangrossi, Jr., “Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviours in the elevated T-maze,” European Journal of Pharmacology, vol. 473, no. 2-3, pp. 153–161, 2003. View at Publisher · View at Google Scholar
101. V. de Paula Soares and H. Zangrossi, Jr., “Involvement of 5-${\text{HT}}_{1\text{A}}$ and 5-${\text{HT}}_2$ receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviours generated by the elevated T-maze,” Brain Research Bulletin, vol. 64, no. 2, pp. 181–188, 2004. View at Publisher · View at Google Scholar · View at PubMed
102. M. J. Caterina, M. A. Schumacher, M. Tominaga, T. A. Rosen, J. D. Levine, and D. Julius, “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature, vol. 389, no. 6653, pp. 816–824, 1997. View at Publisher · View at Google Scholar · View at PubMed
103. A. Szallasi and P. M. Blumberg, “Vanilloid (Capsaicin) receptors and mechanisms,” Pharmacology Reviews, vol. 51, no. 2, pp. 159–212, 1999.
104. M. van der Stelt and V. Di Marzo, “Endovanilloids: putative endogenous ligands of transient receptor potential vanilloid 1 channels,” European Journal of Biochemistry, vol. 271, no. 10, pp. 1827–1834, 2004. View at Publisher · View at Google Scholar · View at PubMed
105. S. Marinelli, V. Di Marzo, F. Florenzano, et al., “$N$-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors,” Neuropsychopharmacology, vol. 32, no. 2, pp. 298–308, 2007. View at Publisher · View at Google Scholar · View at PubMed
106. É. Mezey, Z. E. Tóth, D. N. Cortright, et al., “Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3655–3660, 2000. View at Publisher · View at Google Scholar · View at PubMed
107. S. McGaraughty, K. L. Chu, R. S. Bitner, et al., “Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM,” Journal of Neurophysiology, vol. 90, no. 4, pp. 2702–2710, 2003. View at Publisher · View at Google Scholar · View at PubMed
108. E. Palazzo, V. de Novellis, I. Marabese, et al., “Interaction between vanilloid and glutamate receptors in the central modulation of nociception,” European Journal of Pharmacology, vol. 439, no. 1–3, pp. 69–75, 2002. View at Publisher · View at Google Scholar
109. J. Xing and J. Li, “TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons,” Journal of Neurophysiology, vol. 97, no. 1, pp. 503–511, 2007. View at Publisher · View at Google Scholar · View at PubMed
110. M. L. Molchanov and F. S. Guimarães, “Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats,” Psychopharmacology, vol. 160, no. 1, pp. 30–38, 2002. View at Publisher · View at Google Scholar · View at PubMed
111. R. Marsch, E. Foeller, G. Rammes, et al., “Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice,” The Journal of Neuroscience, vol. 27, no. 4, pp. 832–839, 2007. View at Publisher · View at Google Scholar · View at PubMed
112. V. Micale, L. Cristino, A. Tamburella, et al., “Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels,” Neuropsychopharmacology. In press. View at Publisher · View at Google Scholar · View at PubMed
113. T. Rubino, N. Realini, C. Castiglioni, et al., “Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex,” Cerebral Cortex, vol. 18, no. 6, pp. 292–301, 2008. View at Publisher · View at Google Scholar · View at PubMed
114. T. Rubino, C. Guidali, D. Vigano, et al., “CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour,” Neuropharmacology, vol. 54, no. 1, pp. 151–160, 2008. View at Publisher · View at Google Scholar · View at PubMed
115. E. S. Onaivi, A. Chakrabarti, E. T. Gwebu, and G. Chaudhuri, “Neurobehavioral effects of ${\mathrm{\Delta }}^9$-THC and cannabinoid (CB1) receptor gene expression in mice,” Behavioural Brain Research, vol. 72, no. 1-2, pp. 115–125, 1996. View at Publisher · View at Google Scholar